Opinion
Video
Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars
Panelists discuss how biosimilar manufacturers can increase uptake by ensuring positive financial outcomes for all stakeholders, maintaining strong patient assistance programs, and working closely with health care providers who significantly influence biosimilar implementation.
Manufacturer Partnerships and Biosimilar Value Proposition
Key Themes:
- Financial Viability: Manufacturers must ensure pricing models remain financially viable for providers, avoiding situations where acquisition costs exceed reimbursement due to average selling price depression.
- Prelaunch Planning: Early negotiations prior to product launch enable immediate uptake rather than delayed implementation while terms are finalized.
- Patient Assistance Programs: Biosimilar manufacturers have successfully matched originator patient assistance programs, maintaining financial accessibility for patients.
Key Points for Physicians:
- Ensure biosimilar reimbursement exceeds acquisition cost to maintain financial sustainability.
- Verify patient assistance program availability when transitioning to biosimilars to prevent increased out-of-pocket costs.
- Recognize that health care providers significantly influence biosimilar adoption in both medical and pharmacy benefit spaces.
Notable Insights:
The operational change management burden for pharmacies transitioning patients between products requires proper incentives to justify the effort.
Clinical Significance: Successful biosimilar implementation requires addressing financial viability across the care continuum while ensuring patient affordability, creating alignment among all stakeholders in the delivery system.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
